Enterprise Value
334.1M
Cash
253.7M
Avg Qtr Burn
-21.43M
Short % of Float
17.90%
Insider Ownership
5.59%
Institutional Own.
92.06%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
STK-001 Details Dravet syndrome, Epilepsy | Phase 1/2 Data readout | |
STK-002 (UK) Details Rare genetic disease, Autosomal Dominant Optic Atrophy | Phase 1/2 Initiation |